Oncology R&D: Exploiting New Molecular Targets Is Challenge for 2003
Executive Summary
The next wave of cancer drugs entering late-stage development reflects the improved understanding of cancer biology and oncogenesis made possible by sophisticated genomics and bioinformatics technologies
You may also be interested in...
Genentech Eyes Top Oncology Spot By 2010; No Near-Term Avastin Competitor
Genentech believes the first competitor to its oncologic Avastin in the angiogenesis market is "years away.
Genentech Eyes Top Oncology Spot By 2010; No Near-Term Avastin Competitor
Genentech believes the first competitor to its oncologic Avastin in the angiogenesis market is "years away.
Genitope IPO Would Fund Phase III Cancer Vaccine Trials
Genitope plans to use proceeds from an initial public offering to fund enrollment of 360 patients in a pivotal study of the MyVax therapeutic cancer vaccine